Abstract | BACKGROUND: METHODS: We selected multidrug-resistant human PC-3MM2 prostate cancer cells (termed PC-3MM2-MDR cells) by culturing them in increasing concentrations of paclitaxel. PC-3MM2-MDR cells were implanted into one tibia of 80 nude mice. Two weeks later, the mice were randomly assigned to receive distilled water (control group), paclitaxel, imatinib, or imatinib plus paclitaxel for 10 weeks (20 mice per group). Tumor incidence and weight, bone structure preservation and osteolysis, and the incidence of lymph node metastasis were determined. The phosphorylation status of PDGFR on tumor cells and tumor-associated endothelial cells and levels of apoptosis were examined with immunohistochemical analyses. Microvessel density was assessed as the number of cells expressing CD31/ platelet endothelial cell adhesion molecule 1 (PECAM-1). All statistical tests were two-sided. RESULTS: PC-3MM2-MDR cells were resistant to paclitaxel and imatinib in vitro. Treatment of implanted mice with imatinib plus paclitaxel led to statistically significant decreases in bone tumor incidence (control = 19 mice with tumors of 19 mice total; imatinib plus paclitaxel = four of 18 mice; P < .001), median tumor weight (control = 1.3 g, interquartile range [IQR] = 1.0-1.9; imatinib plus paclitaxel = 0.1 g, IQR = 0-0.3; P < .001), bone lysis, and the incidence of lymph node metastasis (control = 19 of 19 mice total; imatinib plus paclitaxel = three of 18 mice; P < .001). Treatment with imatinib alone had similar effects, and imatinib treatment also inhibited phosphorylation of PDGFR on tumor cells and tumor-associated endothelial cells and increased the level of apoptosis of endothelial cells, but not tumor cells. Treatment with imatinib and more so with imatinib and paclitaxel decreased mean vessel density (three CD31/PECAM-1-positive cells, 95% confidence interval [CI] = 0 to 9; and control group = 38 CD31/PECAM-1-positive cells, 95% CI = 17 to 59) (P < .001), which was followed by apoptosis of tumor cells. CONCLUSION:
|
Authors | Sun-Jin Kim, Hisanori Uehara, Sertac Yazici, Joseph Erik Busby, Toru Nakamura, Junqin He, Marva Maya, Christopher Logothetis, Paul Mathew, Xuemei Wang, Kim-Anh Do, Dominic Fan, Isaiah J Fidler |
Journal | Journal of the National Cancer Institute
(J Natl Cancer Inst)
Vol. 98
Issue 11
Pg. 783-93
(Jun 07 2006)
ISSN: 1460-2105 [Electronic] United States |
PMID | 16757703
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Benzamides
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Imatinib Mesylate
- Protein-Tyrosine Kinases
- Receptors, Platelet-Derived Growth Factor
- Paclitaxel
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Antineoplastic Agents, Phytogenic
(pharmacology)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Apoptosis
(drug effects)
- Benzamides
- Blotting, Western
- Bone Neoplasms
(blood supply, chemistry, prevention & control, secondary)
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Endothelial Cells
(drug effects, metabolism)
- Fluorescent Antibody Technique
- Humans
- Imatinib Mesylate
- Immunohistochemistry
- In Situ Nick-End Labeling
- Lymphatic Metastasis
(prevention & control)
- Male
- Mice
- Mice, Nude
- Microcirculation
(drug effects)
- Neoplasm Transplantation
- Neovascularization, Pathologic
(prevention & control)
- Paclitaxel
(pharmacology)
- Phosphorylation
(drug effects)
- Piperazines
(pharmacology)
- Prostatic Neoplasms
(drug therapy, pathology)
- Protein Kinase Inhibitors
(pharmacology)
- Protein-Tyrosine Kinases
(antagonists & inhibitors)
- Pyrimidines
(pharmacology)
- Random Allocation
- Receptors, Platelet-Derived Growth Factor
(antagonists & inhibitors)
- Reverse Transcriptase Polymerase Chain Reaction
- Tibia
(drug effects, pathology)
- Tumor Cells, Cultured
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|